Mitul Patel, MD
Interventional Cardiology · San Diego, CANPI 1457572448
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.3%), other and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Boston Scientific at 41.3% of the total. 2025 is the largest year on record at $257,462, 4.3 times the $60,280 reported in 2019. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $1045.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$249K
- Medtronic$77K
- Shockwave Medical, Inc$68K
- Abiomed$66K
- Abbott$34K
- Chiesi USA, Inc.$33K
- plus $76K from 29 others
Across 59 payments — averaging $3490.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$61K
- Shockwave Medical, Inc$61K
- Terumo Medical Corporation$41K
- Penumbra, Inc.$37K
- Microvention, Inc.$6K
- Abiomed$150
Across 1 payment — averaging $49,999 each. An ownership or investment interest held by the physician or an immediate family member.
- Vektor Medical Inc.$50K
What the payments were for
- Consulting fees$103,25617%
- Speaking & faculty fees$230,63938%
- Grants$4980%
- Travel & lodging$28,2185%
- Food & beverage$29,0335%
- Education$1530%
- Other$210,43235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 62 | $248,866 |
| Medtronic(2 entities) | 77 | $76,928 |
| Shockwave Medical, Inc | 133 | $67,839 |
| Abiomed | 62 | $66,212 |
| Abbott | 51 | $33,825 |
| Chiesi USA, Inc. | 34 | $32,828 |
| Terumo Medical Corporation | 38 | $23,912 |
| Cardiovascular Systems Inc. | 36 | $20,575 |
| Inari Medical, Inc. | 14 | $14,255 |
| Stryker | 3 | $4,380 |
| Microvention, Inc. | 3 | $3,332 |
| W. L. Gore & Associates, Inc. | 4 | $2,883 |
| Neptune Medical Inc. | 3 | $2,814 |
| Biotronik Inc. | 14 | $624 |
| Edwards Lifesciences | 6 | $554 |
| Reflow Medical Inc | 3 | $272 |
| Asahi Intecc USA, Inc. | 3 | $242 |
| Philips North America LLC | 2 | $233 |
| Siemens Medical Solutions USA, Inc. | 2 | $220 |
| Corindus Inc. | 1 | $206 |
| Impulse Dynamics (USA) Inc. | 1 | $178 |
| Avinger Inc. | 4 | $170 |
| Acist Medical Systems, Inc. | 1 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $147 |
| Cvrx, Inc. | 2 | $145 |
| Cordis US CORP. | 2 | $117 |
| Balt USA, LLC | 1 | $66 |
| AbbVie | 2 | $50 |
| Getinge USA Sales, LLC | 1 | $44 |
| Walk Vascular, LLC | 1 | $37 |
| Cook Medical LLC | 2 | $27 |
| GSK | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$210,734
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$64,414
- Impella$64,367
- Xience V coronary stent system$31,485
- KENGREAL$31,094
- ONYX FRONTIER$28,990
- Resolute$26,464
- FLOWTRIEVER CATHETER, S$18,283
- CT THROMBECTOMY SYSTEM KIT$18,283
- Diamondback Coronary$16,999
- Diamondback Peripheral$12,866
- GENERAL VASCULAR ACCESS$12,502
- RESOLUTE ONYX$10,419
- CROSSBOSS$8,539
- GlideWire$8,466
- Glidesheath$7,911
- METACROSS OTW$5,966
- TR Band$5,775
- Coronary Orbital Atherectomy System$3,960
- Navicross$3,325
How this compares
$602,228 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 35 | $334 |
| Rosuvastatin Calcium | 16 | $273 |
| Atorvastatin Calcium | 23 | $242 |
| Carvedilol | 17 | $208 |
| Losartan Potassium | 24 | $201 |
| Metoprolol Succinate | 24 | $190 |
| Amlodipine Besylate | 12 | $116 |
| Metoprolol Tartrate | 16 | $93 |
| Furosemide | 18 | $76 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in San Diego
- Raghava GollapudiSan Diego$499K
- Luke OakleySan Diego$317K
- Justin CoxSan Diego$291K
- Arvin NarulaSan Diego$163K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.